• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-Analysis Results: Intrahepatic Cholestasis, Ursodeoxycholic Acid Treatment and Pregnancy Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • PITCHES RCT: Ursodeoxycholic acid (UDCA) was not associated with a significant benefit for a composite outcome (stillbirth, preterm birth, and neonatal unit admission)
  • Ovadia et al. (The Lancet Gastroenterology & Hepatology, 2021) evaluated whether UDCA affects specific adverse perinatal outcomes

METHODS:

  • Systematic review and individual participant data meta-analysis
  • Study inclusion criteria
    • ≥30 study participants
    • ≥1 individual with intrahepatic cholestasis of pregnancy (ICP) and bile acid concentrations of ≥40 μmol/L 
  • Study design
    • Individual participant data were collected from the authors
      • Subgroup analyses: Limited to RCTs, singletons or 2 arm studies
    • Mixed-effects meta-analysis used for calculations
    • Adjustments made for bile acid concentration, parity, and multifetal pregnancy
  • Primary outcome
    • The prevalence of stillbirth
  • Secondary outcomes
    • Main secondary outcome (authors anticipate lack of power to assess stillbirth): Composite of stillbirth and preterm birth
    • Other secondary outcomes: Pregnancy complications | Mode of delivery | Onset of labor  

RESULTS:

  • 34 studies
    • Individual participant data: 32 published studies
    • 2 unpublished cohort studies
  • 6974 women
    • UDCA users: 67.8%
  • There was no significant difference in stillbirth between women with ICP who took UDCA and non-users
    • UDCA: 0.7% (35 of 5097 fetuses)
    • Non-users: 0.6% (12 of 2038 fetuses)
    • Adjusted odds ratio (aOR) 1.04 (95% CI, 0.35 to 3.07; P = 0.95)
  • UDCA had no effect on the prevalence of stillbirth when only RCTs were examined
    • aOR 0.29 (95% CI, 0.04 to 2.42; P = 0.25)
  • UDCA had no effect on the composite outcome in all studies
    • aOR 1.28 (95% CI, 0.86 to 1.91; P = 0.22)
  • Based on individual participant data and following adjustments for covariates, UDCA was associated with
    • Reduced composite outcome: aOR 0.68 (95% CI, 0.48 to 0.97)
    • Reduced spontaneous preterm birth (<37 weeks): aOR 0.54 (95% CI, 0.31 to 0.94)  
  • Reduction in composite outcome and preterm birth was also seen in RCTs that only included singleton pregnancies
  • Limiting analyses to RCTs only
    • UDCA significantly reduced the composite outcome with number needed to treat of 15 (95% CI, 9 to 54)

CONCLUSION:

  • For women with ICP, taking UDCA had no effect on the incidence of stillbirth but result likely underpowered
  • Limiting analysis to RCTs, UDCA was associated with a reduction in a composite of stillbirth and preterm birth
  • The authors conclude

In summary, this meta-analysis suggests that ursodeoxycholic acid treatment in women with intrahepatic cholestasis of pregnancy reduces the risk of preterm birth

Previous work has shown that there is an increased risk of preterm birth in women with peak bile acid concentrations of 40 μmol/L or more …

…ursodeoxycholic acid treatment should therefore be considered for these women with disease onset before 37 weeks’ gestation

Learn More – Primary Sources:

Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

PITCHES RCT: Ursodeoxycholic Acid and Intrahepatic Cholestasis of Pregnancy
More from the PITCHES Trial: Subgroup Analysis of Participants with Intrahepatic Cholestasis of Pregnancy and UDCA Treatment
Risk of Stillbirth with Intrahepatic Cholestasis of Pregnancy: What do Bile Acid Concentrations Tell Us?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site